Date: 2012-11-05
Type of information: Grant
Company: PsiOxus Therapeutics (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £1.7m (€2.1 million)
Funding type: grant
Planned used: The funding will be use to initiate a clinical trial to assess the use of its ColoAd1 oncolytic vaccine in the treatment of platinum-resistant, recurrent ovarian cancer.
Others: PsiOxus Therapeutics, a development stage biotechnology company developing novel therapeutics for cancer and other clinically unmet diseases, will receive £1.7m to accelerate the translation of scientific ideas into commercial propositions. The award was announced by Technology Strategy Board and is one of 32 projects awarded funding totalling £39 million. These are the first substantial awards made from the £180 million Biomedical Catalyst programme managed by the Technology Strategy Board and the Medical Research Council.
PsiOxus will initiate a phase I/II clinical trial to assess the use of its ColoAd1 oncolytic vaccine in the treatment of platinum-resistant, recurrent ovarian cancer. The OCTAVE (Ovarian Cancer Treated with Adeno Virus) will assess over 50 ovarian cancer patients and will be carried out at multiple UK cancer centres beginning in 2013. Professor Iain McNeish, from the Institute of Cancer Sciences at the University of Glasgow, is Principal Investigator. This study will be the second clinical trial of ColoAd1. In September, the company has treated the first patient in its first phase I/II clinical trial of ColoAd1, the Evolve (EValuating OncoLytic Vaccine Efficacy) study.
Therapeutic area: Cancer - Oncology
